Developing new drugs to target a key gene in acute myeloid leukemia
A Multiplatform Approach to Develop ENL-Targeting Molecules as Drug Candidates for Acute Myeloid Leukemia
This study is looking at a gene called MLL that often causes problems in people with acute myeloid leukemia (AML), and the researchers want to find new medicines that can better target a related protein to help improve treatment and survival for patients with this blood cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas A&m University NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project ID | NIH-11089398 on NIH RePORTER |
What this research studies
This research focuses on acute myeloid leukemia (AML), a serious blood cancer that requires urgent treatment. The team is investigating a specific gene, MLL, which is often mutated in AML and is linked to poor patient outcomes. They aim to create new drug candidates that can effectively target the ENL protein associated with MLL mutations. By using advanced techniques to analyze the effectiveness of these compounds, they hope to identify promising therapies that could improve survival rates for patients with AML.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia, particularly those with mutations in the MLL gene.
Not a fit: Patients with other types of leukemia or those whose AML does not involve MLL mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, more effective treatments for patients with acute myeloid leukemia.
How similar studies have performed: Previous research has shown promise in targeting similar genetic alterations in leukemia, indicating potential for success in this approach.
Where this research is happening
College Station, United States
- Texas A&m University — College Station, United States (Active)
Researchers
- Principal investigator: Liu, Wenshe Ray — Texas A&m University
- Study coordinator: Liu, Wenshe Ray
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.